## Edgar Filing: TENET HEALTHCARE CORP - Form 4

TENET HE Form 4 March 03, 2	ALTHCARE CO	RP	-							
FORM	ЛЛ								PPROVA	L
	UNITED	O STATES SECURITIES AND EXCHANGE Washington, D.C. 20549					COMMISSIO	N OMB Number:	3235-	0287
Check t if no lor subject Section Form 4	nger <b>STATEN</b> to <b>STATEN</b> 16. or			SECU	RITIES		WNERSHIP OF	Estimated burden hou response	ours per	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> Cancelmi Daniel J			2. Issuer Name <b>and</b> Ticker or Trading Symbol TENET HEALTHCARE CORP			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
			[THC]				(	·····	- /	
(Last) 1445 ROSS	3. Date of Earliest Transaction (Month/Day/Year) 03/01/2017			Director 10% Owner X Officer (give title Other (specify below) below) Chief Financial Officer						
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
DALLAS,	TX 75202						Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	1
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	Date, if	Code Disposed of (D) Year) (Instr. 8) (Instr. 3, 4 and 5) (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature Indirect Beneficia Ownersh (Instr. 4)	ıl	
Damin Jaw D	nont on a commute 1'	for a 1	ooo of			(D) Price	on in dimostler			
keminder: Re	port on a separate line	e for each cl	ass of sec	unities bene:	Perso inform requir	ns who rest nation cont ed to resp ys a curre	or indirectly. spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

## Edgar Filing: TENET HEALTHCARE CORP - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	nstr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)						
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amoun or Numbe of Shar
2017 March Restricted Stock Units	<u>(1)</u>	03/01/2017		А		40,373		<u>(1)</u>	<u>(1)</u>	Common Stock	40,37
2017 March Performance Stock Options (Right to Buy)	\$ 18.99	03/01/2017		А		89,976		<u>(2)</u>	03/01/2027	Common Stock	89,97

## **Reporting Owners**

Reporting Owner Name / Address	Relationships							
1	Director	10% Owner	Officer	Other				
Cancelmi Daniel J 1445 ROSS AVENUE SUITE 1400 DALLAS, TX 75202			Chief Financial C	Officer				
Signatures								
Anthony L. Shoemaker, as Atto Cancelmi	iel J.	03/03/2017						

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These time-based restricted stock units vest in one-third increments on each of the first, second and third anniversaries of the date of grant. Restricted stock units are settled in shares of the Company's common stock upon vesting.
- These performance-based stock options vest on the third anniversary of the date of grant, subject to the satisfaction of a stock price(2) performance condition requiring the Company's common stock price to close at or above \$23.74 per share for any 20 consecutive trading days during the three-year period following the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.